Personalized radiotherapy: incorporating cellular response to irradiation in personalized treatment planning to minimize radiation toxicity
(REQUITE extended follow-up)
Aim of the Study
The aim of this international study is to personalize radiotherapy treatment for cancer patients by improving prediction models for the risk of long-term side effects after radiotherapy. The information from prediction models including biomarker information from blood samples will then be incorporated into treatment planning systems. This gives the chance to individualize radiotherapy treatment for each patient.
Why are we doing this study?
About half of all cancer patients receive radiotherapy. Approximately 5% of patients (5 out of 100) are particularly sensitive to irradiation, making them more likely than others to developing side effects after radiotherapy. Side effects can occur years after radiotherapy and impair quality of life. Building on data and results from the previous REQUITE study (www.requite.eu), the goal of the RADprecise project is to predict which patients are more likely to develop long-term side effects after radiotherapy. We also want to test additional biomarkers in the blood as markers of radiation sensitivity. The data and samples collected in this project will also provide a valuable resource for future research.
What is the RADprecise study?
A cohort of breast and prostate cancer patients (Germany, Italy, Spain and the United Kingdom) from the REQUITE project will be invited to take part in the RADprecise project which includes a follow-up extension to five years or longer after radiotherapy.
Participating patients are asked to complete the same questionnaires as used previously about their health, symptoms after radiotherapy and quality of life. They will also be asked for another blood sample which will be screened in the lab for further biomarkers that may be related to radiation sensitivity.
Illustration
Who is conducting the project?
The project is being coordinated by the German Cancer Research Center (DKFZ) in Heidelberg, Germany. Hospitals in Germany, Italy, Spain and United Kingdom participate, together with further partners from academia / health research and two French companies. The project is funded via the ERA PerMed network 2018 (www.erapermed.eu) and the national funding organisations BMBF (Germany), ANR (France), DS-CAT (Spain), ICSIII (Spain) and FRRB (Italy).
© freepik
- Prof. Dr. Jenny Chang-Claude, German Cancer Research Center (DKFZ), Heidelberg, Germany (coordinator) https://www.dkfz.de/en
- Dr. David Gibon, Aquilab, Loos, France https://www.aquilab.com/
- Dr. Sara Gutiérrez-Enríquez, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain http://www.vhio.net/en/
- Dr. Tiziana Rancati, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy https://www.istitutotumori.mi.it/
- Dr. Ana Vega, Fundación Pública Galega Medicina Xenómica (FPGMX), Santiago de Compostela, Spain https://www.xenomica.eu/?lang=en
- Prof. Paolo Zunino, Politecnico di Milano (POLIMI), Milan, Italy https://www.polimi.it/en
- Sylvie Sauvaigo, LXRepair, La Tronche, France https://www.lxrepair.com/
- collaborative partner: Dr. Christopher J Talbot, University of Leicester (ULEIC), Leicester, UK https://le.ac.uk/